Emerging pharmacological therapies (i.e. ketamine, esketamine) show efficacy in treatment resistant depression; however, there is less data on their cost-effectiveness which is important for funding through governments and insurers.
Dr Chatterton will present the methods and results of a within-trial cost-utility analysis from the Ketamine in Adult Depression (KADS) study.
The trial involved 174 participants receiving ketamine or midazolam (active control) twice weekly for 4 weeks. Healthcare resource use, transportation, carer time and lost productivity data were collected via self-reported questionnaire at baseline, end of RCT (week 4) and RCT 4-week follow-up (week 8). Quality-adjusted life years (QALYs) were calculated using AQoL-8D utility values
Presenter
Dr Mary Lou Chatterton is a Senior Research Fellow and Co-Program Lead for Mental Health at Monash University Health Economics Group. She has a doctorate in clinical pharmacy and a PhD in health economics.
Dr Chatterton’s health economics research has spanned a variety of clinical areas. Her current work is focused on economic evaluations of interventions to prevent and treat mental health conditions including bipolar disorder, schizophrenia, anxiety and depression.